Werewolf Therapeutics, Inc
Price
FilingsNewest: 13G, Stake over 5%, passiveSep 21 →InsidersNo open-market buys. 17 insiders sold $8.6M, 140 of 160 sales on a 10b5-1 plan.→HoldersRa 4.9%Balyasny 3.7%Vanguard 2.5%→Financing →PeersClosest companies: XLO, CCCC, BDTX→
From the filings
Figures
- Net income
- −$34.6Mlast 12 months
- Operating cash flow
- −$51.9Mlast 12 months
- Cash and equivalents
- $22.0Mat the last balance sheet
- Total debt
- $32.1Mat the last balance sheet
- Shares outstanding
- 48.6M shareson issue